LADAR 6000 offers good visual outcomes

Article

The LADAR 6000 excimer laser with high-speed ablation (Alcon) offers excellent visual outcomes, according to Ángel López Castro of Spain, speaking at the Alcon symposium.

The LADAR 6000 excimer laser with high-speed ablation (Alcon) offers excellent visual outcomes, according to Ángel López Castro of Spain, speaking at the Alcon symposium.

Dr López Castro conducted a study comparing conventional and custom treatments using the LADAR system. A total of 115 eyes were enrolled in the study with 110 receiving the custom LASIK and 14 the conventional treatment.

At three months, two-thirds of eyes in the custom group were within 0.25 D mean refractive spherical equivalent (MRSE) of their intended target, compared with around half of those in the conventional treatment group. 70% of eyes achieved a postoperative uncorrected visual acuity (UCVA) equal to or better than their preoperative best corrected visual acuity (BCVA) as opposed to just 57% of the conventionally treated group.

López Castro discussed what he sees as the benefits of the new system: more surgeon control, enhanced ergonomics, improved patient comfort. Finally he remarked on the LADAR 6000's speed; it is 50% faster than Alcon's previous system. Treatments can now be completed in less than 60 seconds, which may offer potential postoperative benefits.

Dr López Castro concluded that the LADAR 6000 is able to offer good visual outcomes for the patient whilst also offering the surgeon a more efficient, simpler-to-use system.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.